Oncolytic therapy with a dual hdac3 and hdac8 targeting agent
AssigneeUniversity of Florida Research Foundation, Inc.
InventorsBeth A. Rousseau, Sumita Bhaduri-Mclntosh, Michael Mclntosh, Guangrong Zheng, Yufeng Xiao
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating or preventing a disease associated with a virus, methods of inhibiting cell proliferation or promoting apoptosis, methods of inducing a lytic phase of a virus, and methods of reactivating a virus by administering to a subject in need thereof a dual HDAC3 and HDAC8 targeting agent and an antiviral, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.
Claims32
A method of treating or preventing a disease associated with a virus in a subject in need thereof, the method comprising administering to the subject in need thereof a therapeutically effective amount of a dual HDAC3 and HDAC8 targeting agent, or a pharmaceutically acceptable salt thereof.
3-18. (canceled)
(canceled)
25-26. (canceled)
(canceled)
31-32. (canceled)
(canceled)
(canceled)
38-45. (canceled)
A method of inhibiting cell proliferation or promoting apoptosis in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of a dual HDAC3 and HDAC8 targeting agent, or a pharmaceutically acceptable salt thereof.
A method of inducing a lytic phase of a virus in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of a dual HDAC3 and HDAC8 targeting agent, or a pharmaceutically acceptable salt thereof.
48-73. (canceled)
76-77. (canceled)
79-89. (canceled)
92-112. (canceled)
Dependencies are inferred from the claim text.